LI
RANI icon

Lafayette Investments’s Rani Therapeutics RANI Stock Holding History

Lafayette Investments’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.9K Hold
22,979
– – ﹤0.01% 158
2025
Q4 		$31K Buy
22,979
+3,086
+16% +$4.66K 0.01% 155
2025
Q3 		$9.94K Hold
19,893
– – ﹤0.01% 156
2025
Q2 		$10.2K Hold
19,893
– – ﹤0.01% 151
2025
Q1 		$25.1K Hold
19,893
– – 0.01% 145
2024
Q4 		$27.3K Hold
19,893
– – 0.01% 148
2024
Q3 		$43K Hold
19,893
– – 0.01% 145
2024
Q2 		$75.6K Hold
19,893
– – 0.02% 141
2024
Q1 		$61.9K Hold
19,893
– – 0.01% 140
2023
Q4 		$66K Hold
19,893
– – 0.02% 133
2023
Q3 		$43.3K Hold
19,893
– – 0.01% 126
2023
Q2 		$82K Hold
19,893
– – 0.02% 124
2023
Q1 		$103K Hold
19,893
– – 0.03% 121
2022
Q4 		$117K Hold
19,893
– – 0.03% 118
2022
Q3 		$191K Buy
+19,893
New +$211K 0.06% 111

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Lafayette Investments's RANI Position: Q1 2026 in Review

Lafayette Investments held its Rani Therapeutics (RANI) position steady in Q1 2026 at 22,979 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #158.

Lafayette Investments first reported a position in RANI in Q3 2022 and has held it in 15 quarters since. The position peaked at $191K in Q3 2022. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Lafayette Investments held 22,979 shares of Rani Therapeutics worth $16.9K as of Q1 2026.
  • Lafayette Investments left its Rani Therapeutics share count unchanged in Q1 2026.
  • Rani Therapeutics made up ﹤0.01% of Lafayette Investments's portfolio in Q1 2026, its #158 holding.
  • Lafayette Investments first reported a position in Rani Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Lafayette Investments's Rani Therapeutics position peaked at $191K in Q3 2022.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Lafayette Investments's 13F filing for Q1 2026, filed 27 Apr 2026.